ArticleAmerican journal of translational research2025
Impact of oryzanol plus femoston on efficacy, sleep quality, and quality of life in perimenopausal syndrome patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic impact of Oryzanol combined with Femoston on symptom relief, sleep quality, and quality of life in patients with perimenopausal syndrome (PMS).
methodsA total of 201 PMS patients were included and allocated into two groups based on treatment: Femoston monotherapy (control) and Femoston plus Oryzanol (research group). Clinical outcomes were compared, including overall efficacy, adverse events, sex hormone levels, endometrial thickness, bone mineral density (BMD), lipid profiles, neurotransmitter concentrations, sleep quality, and quality of life.
resultsThe research group demonstrated significantly higher therapeutic efficacy than the control group, with fewer adverse events. Post-treatment improvements were more pronounced in the research group across multiple parameters, including hormonal balance, endometrial thickness, BMD, lipid metabolism, neurotransmitter activity, sleep quality, and overall quality of life (all P<0.05).
conclusionsCo-therapy with Oryzanol and Femoston is highly effective for PMS management. It alleviates neurological symptoms, corrects lipid abnormalities, improves sleep, enhances quality of life, and provides measurable benefits for endometrial and BMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.